Clobetasol Propionate
Rank #250 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$51.2M
Total Cost
758,575
Total Claims
$51.2M
Total Cost
19,226
Prescribers
$67
Cost per Claim
365,596
Beneficiaries
816,495
30-Day Fills
$2,663
Avg Cost/Provider
39
Avg Claims/Provider
Share of Medicare Part D Spending
0.02%
of total Medicare Part D spending
$51.2M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $51.2M total
Top Prescribers of Clobetasol Propionate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Sharene Nubani | Podiatry | Dorchester, MA | 1,372 | $442K |
| 2 | Roberto Carpio | Nurse Practitioner | North Hills, CA | 815 | $309K |
| 3 | Rachel Reece | Podiatry | Bronx, NY | 663 | $213K |
| 4 | Navid Ezra | Dermatology | Thousand Oaks, CA | 885 | $187K |
| 5 | Karina Torres | Nurse Practitioner | Miami, FL | 1,656 | $147K |
| 6 | Peter Hu | Physician Assistant | Brooklyn, NY | 627 | $138K |
| 7 | Mazda Alaie | Podiatry | Bronx, NY | 394 | $127K |
| 8 | Mohammed Yousuf | Podiatry | Bronx, NY | 336 | $107K |
| 9 | Kelvin Mai | Internal Medicine | Santa Ana, CA | 433 | $99K |
| 10 | Vlad Nusinovich | Internal Medicine | West Hollywood, CA | 244 | $91K |
| 11 | Pinkas Lebovits | Dermatology | New York, NY | 737 | $85K |
| 12 | Jimmy Van | Orthopaedic Surgery | Brooklyn, NY | 457 | $82K |
| 13 | Ramsey Joudeh | Internal Medicine | Brooklyn, NY | 196 | $79K |
| 14 | Xiangsheng Zheng | Internal Medicine | Birmingham, AL | 557 | $76K |
| 15 | Mariano Sapien | Podiatry | El Paso, TX | 187 | $76K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 247 | Ranolazine (Ranolazine Er) | $51.6M | 381,631 |
| 248 | Epoetin Alfa (Epogen) | $51.4M | 34,952 |
| 249 | Nifedipine (Nifedipine Er) | $51.2M | 1,249,866 |
| 250 | Clobetasol Propionate (Clobetasol Propionate) | $51.2M | 758,575 |
| 251 | Sodium,calcium,mag,pot Oxybate (Xywav) | $51.1M | 3,234 |
| 252 | Eslicarbazepine Acetate (Aptiom) | $51.1M | 31,472 |
| 253 | Risdiplam (Evrysdi) | $51.1M | 1,891 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology